Aptamer Group
Aptamer Group
Delivering on target
At Aptamer Group we help customers select ssDNA or RNA aptamers against their target of interest for development as potential research tools, diagnostic reagents, biomarker discovery tools or bio-therapeutics.
Aptamers have multiple benefits as binding molecules:
– Improved affinity
– Reproducibility
– Stability
– Low batch-to-batch variability
– Tuneable specificity
– Cheap large scale costs
– Produced to any target
– Excellent QC in manufacture
– No cold chain supply
– No intrinsic immune response
– Works in multiple matrices
About Aptamer Group
Aptamer Group is a biotechnology company founded in 2008 by Dr Arron Tolley (CEO) & Dr David Bunka (CSO). It was established based on their expertise and evolving technology to develop aptamers, nucleic acid molecule alternatives to antibodies, which bind the specified target with the required affinity and selectivity.
Aptamer Group is a key player in the aptamer selection market offering customers access to an accelerated aptamer selection platform that delivers tailor-made high-affinity, high specificity molecules for use in a variety of scenarios.
Aptamer Selection
Targets that are potentially amenable to aptamer selection include: peptides, proteins, viruses, cells, tissue samples (fresh and fixed), micro-organisms and small molecules.
The ability to select aptamers that bind to small molecules is a key differentiator from antibodies where the target needs to be immunogenic. During selection it is possible to introduce counter-selection molecules to remove aptamers that will bind to moieties closely related to the target. Counter-selection drives selectivity to the target of interest.
The aptamer selection process utilises our automated high-throughput robotic selection platform. This enables rapid delivery of aptamers with the required specificity and binding characteristics monoclonal aptamers typically being delivered in 12 weeks.
It is possible to modify selected aptamers in a number of ways. Stability can be improved in-vivo, chemical groups can be attached dependent on the intended final application.
Aptamer Application
After selection, Aptamer Group can support the development of aptamers for numerous life sciences applications:
– Research: aptamers can be used in Flow Cytometry, Mass Spectrometry, Western Blotting, Sandwich Assays (ELONA), detection of targets in FFPE tissue, Fluorescence microscopy
– Drug Discovery: identification of potential therapeutic targets
– Biosensors: Lateral Flow Devices, Dip & Read biosensors, Electro-chemiluminescence, multiple fluorophores enables multiplexed assays
– Diagnostics: clinical support, food and environmental contamination monitoring
– Biomarker Discovery: aptamers against disease associated cell surface proteins
– Therapeutics: targeted drug delivery, ADCs, novel therapeutics (AMD, cancer)
– Biopharmaceutical Manufacture: Protein Purification / Down Stream Processing
Aptamer Group
Your target is our objective
Website: www.aptamergroup.co.uk
E-mail: info@aptamergroup.co.uk
Phone: +44 (0)1904 567790
Aptamer Group Introduces Novel Biomarker Discovery Service
Agreement to Explore Optimer Vehicles for Targeted Delivery of siRNA
+44 (0)1904 567790
